2014
DOI: 10.1097/bco.0000000000000122
|View full text |Cite
|
Sign up to set email alerts
|

Factors associated with hip arthroscopy complications in the treatment of femoroacetabular impingement

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(6 citation statements)
references
References 13 publications
0
6
0
Order By: Relevance
“…PO by mouth, BD twice a day, QD once daily, RR risk ratio Author Group 1 (number of hips) Group 2 (number of hips) Ho 1 HO 2 Effect of prophylaxis Beckmann [ 26 ] Naproxen 500 mg PO BD, 3 weeks (48) Placebo (48) 2/48 (4.2%) 22/48 (45.8%) RR 0.09 for HO in group 1 compared to group 2 ( P < 0.001) Beckmann [ 36 ] Naproxen 500 mg PO BD, 3 weeks (196) No prophylaxis (92) 11/196 (5.6%) 23/92 (25.0%) Ho 13.6 times more likely in no prophylaxis group ( P = 0.003) Bedi [ 24 ] Naproxen 500 mg PO BD, 30 days (277) Indomethacin 75 mg QD, 4 days, followed by naproxen 500 mg PO BD for 30 days and omeprazole 20 mg daily for first 4 days (339) 23/277 (8.3%) 6/339 (1.8%) Ho 4.6 times more likely in group 1 ( P < 0.05). no significant difference between the groups in the likelihood of developing HO with a Brooker grade > 1 Dow [ 42 ] Celecoxib 400 mg QD, 6 weeks (243) No prophylaxis (211) 30/131 (22.9%) (112 pts lost to follow-up) 62/ 173 (35.8%) (38 pts lost to follow-up) Significantly reduced incidence of HO in group 1 ( P < 0.001) Mortensen [ 54 ] Naproxen 500 mg PO BD, 2 weeks (185) Naproxen 500 mg PO BD, 3 weeks (48) 5/185 (2.7%) 2/48 (4.2%) No significant difference in HO incidence between groups Nossa [ 56 ] Celecoxib 200 mg QD, 3 weeks (122) No prophylaxis (240) ...…”
Section: Resultsmentioning
confidence: 99%
“…PO by mouth, BD twice a day, QD once daily, RR risk ratio Author Group 1 (number of hips) Group 2 (number of hips) Ho 1 HO 2 Effect of prophylaxis Beckmann [ 26 ] Naproxen 500 mg PO BD, 3 weeks (48) Placebo (48) 2/48 (4.2%) 22/48 (45.8%) RR 0.09 for HO in group 1 compared to group 2 ( P < 0.001) Beckmann [ 36 ] Naproxen 500 mg PO BD, 3 weeks (196) No prophylaxis (92) 11/196 (5.6%) 23/92 (25.0%) Ho 13.6 times more likely in no prophylaxis group ( P = 0.003) Bedi [ 24 ] Naproxen 500 mg PO BD, 30 days (277) Indomethacin 75 mg QD, 4 days, followed by naproxen 500 mg PO BD for 30 days and omeprazole 20 mg daily for first 4 days (339) 23/277 (8.3%) 6/339 (1.8%) Ho 4.6 times more likely in group 1 ( P < 0.05). no significant difference between the groups in the likelihood of developing HO with a Brooker grade > 1 Dow [ 42 ] Celecoxib 400 mg QD, 6 weeks (243) No prophylaxis (211) 30/131 (22.9%) (112 pts lost to follow-up) 62/ 173 (35.8%) (38 pts lost to follow-up) Significantly reduced incidence of HO in group 1 ( P < 0.001) Mortensen [ 54 ] Naproxen 500 mg PO BD, 2 weeks (185) Naproxen 500 mg PO BD, 3 weeks (48) 5/185 (2.7%) 2/48 (4.2%) No significant difference in HO incidence between groups Nossa [ 56 ] Celecoxib 200 mg QD, 3 weeks (122) No prophylaxis (240) ...…”
Section: Resultsmentioning
confidence: 99%
“…The present results show that HBO therapy has good clinical efficacy in the treatment of early stages of femoral head necrosis and pain. The clinical effect is similar to that of celecoxib [43,44]. In particular, high-pressure oxygen is a good choice for patients who have a high-sensitivity drug allergy, high blood pressure, and gastrointestinal disease.…”
Section: Discussionmentioning
confidence: 66%
“…After taking the drug, the action is quick and pain relief is remarkable; however, the maintenance time is short and the biggest problem is the adverse drug reaction [41][42][43][44]. Although celecoxib is the nonsteroidal antiinflammatory analgesic drug eliciting the smallest gastrointestinal tract reaction, clinical use still results in gastrointestinal discomfort in numerous patients.…”
Section: Discussionmentioning
confidence: 99%
“…The criteria of the grading of HO in the Brooker system are described in the earlier section on classification. In the remaining study by Nossa et al, 14 HO was one of the complications recorded by the surgeons during follow-up, but further details of their diagnostic criteria for HO were not specified in their description of methodology, and it was unclear whether the Brooker classification was used. Attempts were made to contact the authors to clarify this methodology, but these attempts were unsuccessful.…”
Section: Study Characteristicsmentioning
confidence: 97%